Effect of Compound Amino Acid Tablets on Nutritional Status of Patients With Lung Cancer

March 14, 2023 updated by: Zhuo Li, Beijing Chest Hospital
To investigate whether compound amino acid supplementation can further promote protein synthesis and improve nutritional status for lung cancer patients.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

86

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • NRS2002 >=3 scores
  • lung cancer patients
  • low albumin or hemoglobin
  • informed consent

Exclusion Criteria:

  • Acute and critical patients;
  • Severe liver and kidney dysfunction;
  • Patients with gastrointestinal bleeding or intestinal obstruction;
  • Pregnant women, lactating women, people with mental illness, and people without independent behavior ability.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: control group
placebo
Dietary supplement: amino acid tablet
multiple essential amino acids supplements
Experimental: intervention group
compound amino acid supplement
Dietary supplement: amino acid tablet
multiple essential amino acids supplements

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Concentration of albumin
Time Frame: after 42 days after the intervention
after 42 days after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Chest Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 15, 2023

Primary Completion (Anticipated)

July 30, 2023

Study Completion (Anticipated)

August 30, 2023

Study Registration Dates

First Submitted

February 21, 2023

First Submitted That Met QC Criteria

March 14, 2023

First Posted (Actual)

March 15, 2023

Study Record Updates

Last Update Posted (Actual)

March 15, 2023

Last Update Submitted That Met QC Criteria

March 14, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • YNLX-2022-011

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe